Theolytics Ltd.

https://www.theolytics.com

LinkedIn: https://www.linkedin.com/company/theolytics

Theolytics is focused on developing category changing cancer therapies in the form of oncolytic viruses. The company is pioneering a phenotypic screening approach to the discovery and development of efficacious, targeted candidates suitable for intravenous delivery and optimised for a chosen patient population. Theolytics, which was founded in 2017 and is headquartered in Oxford, UK, backed by Oxford Science Innovation (OSI) and international life sciences investors Epidarex Capital, Taiho Ventures, and M Ventures. *

	Start	2017-12-01 established (s-off)
	Predecessor	University of Oxford
	Industry	BIOTECH
	Industry 2	oncolytic virus technology
	Person	Casebourne, Charlotte (Theolytics 202107 CEO + Co-Founder)

	Region	Oxford, Oxfordshire
	Country	United Kingdom (GB)
	Street	Roosevelt Drive Innovation Building
	City	OX3 7FZ Oxford, Oxfordshire
		Address record changed: 2024-01-05

Basic data	Employees	B: 11 to 50 (2021-06-26)

		* Document for »About Section«: Theolytics Ltd.. (7/8/21). "Press Release: Theolytics Expands Series A Financing and Welcomes M Ventures as a New Investor". Oxford.

		Record changed: 2025-03-16